Application of CD19-CART cells in B-cell lymphocytic leukemia

find out the optimal number of CART cells for anti-tumor effects. In this study, 10 patients with
relapsed and refractory CLL were enrolled. All patients were treated with CART cells, of whom 6
were treated with low amounts (5×107) and 4 patients were treated with high amounts (5×108).
The median follow-up was 3 months. There was no significant difference in the efficacy and
adverse reactions between the two groups.
The use of CART cells to specifically target CD19-positive B-cell lymphoma and leukemia
patients has achieved significant clinical efficacy and is expected to be widely used. Although the
current CART treatment is carried out for a short period of time, there is still a lack of large-scale
samples, and many adverse reactions and complications need to be gradually discovered and
resolved in clinical trials. However, in the clinical trials reported for the treatment of B-cell
lymphoma and leukemia, CART showed a very significant effect, especially for relapsed and
refractory patients, thus providing a basis for a larger-scale, multi-center clinical study.
Author Bio
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists
located in different continents working closely with partners from the entire world to develop and
produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and
CAR T&NK cell immune therapy development, as we offer the one-stop custom services that
cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of
ready-to-use TCR T and CAR T&NK cell construction products, such as virus packaging,
purification, expansion and titer determination kits. Furthermore, we have built up a unique
unparalleled CAR construction and production platform for all four CAR generations.